摘要
目的:探讨替雷利珠单抗联合化疗用于老年肺癌的效果。方法:回顾性选取2022年7月—2024年2月福清市医院收治的80例老年肺癌一线治疗患者(≥65岁)为研究对象,根据治疗方案不同分组,对照组(n=40)采取化疗,观察组(n=40)再加替雷利珠单抗,评估治疗情况。结果:观察组客观缓解率(ORR)更高,中位无进展生存期更长,差异有统计学意义(P<0.05)。治疗后,相较对照组,观察组上述指标明显更低,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:替雷利珠单抗联合化疗用于老年肺癌一线治疗中疗效提高,不良反应无明显增加,安全可控。
Objective:To investigate the efficacy of trastuzumab combined with chemotherapy in elderly patients with lung cancer.Method:A retrospective selection was made of 80 elderly patients(≥65 years old)with first-line lung cancer admitted to Fuqing Hospital from July 2022 to February 2024.According to different treatment plans,the control group(n=40)received chemotherapy,while the observation group(n=40)received additional treatment with trastuzumab.The treatment status was evaluated.Result:The objective response rate(ORR)of the observation group was higher,and the median progression free survival was longer,and the differencese were statistically significant(P<0.05).After treatment,compared with the control group,the above indicators in the observation group were significantly lower,and the differences were statistically signticant(P<0.05).There was no significant difference in adverse reactions between the two groups,and the differencese were statistically significant(P>0.05).Conclusion:Tislelizumab combined with chemotherapy has improved efficacy in the first-line treatment of elderly lung cancer,with no significant increase in adverse reactions and is safe and controllable.
作者
高晨杨
GAO Chenyang(Fuqing City Hospital,Fuqing 350300,China)
出处
《中外医学研究》
2025年第35期1-5,共5页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
替雷利珠单抗
化疗
老年
肺癌
疗效
安全性
Tislelizumab
Chemotherapy
Elderly
Lung cancer
Efficacy
Safety
